View More Recent Stories

Apr 14, 2023 01:30AM Relief Therapeutics Announces Full Year 2022 Financial Results and Provides Corporate Update
Apr 5, 2023 01:30AM Relief Therapeutics Announces Executive Leadership Team Change
Apr 4, 2023 01:12AM Relief Therapeutics Holding SA to Hold Extraordinary General Meeting of Shareholders
Apr 4, 2023 01:12AM Relief Therapeutics Holding SA to Hold Extraordinary General Meeting of Shareholders
Apr 4, 2023 01:12AM Relief Therapeutics Holding SA to Hold Extraordinary General Meeting of Shareholders
Apr 4, 2023 01:12AM Relief Therapeutics Holding SA to Hold Extraordinary General Meeting of Shareholders
Apr 4, 2023 01:12AM Relief Therapeutics Holding SA to Hold Extraordinary General Meeting of Shareholders
Apr 4, 2023 01:12AM Relief Therapeutics Holding SA to Hold Extraordinary General Meeting of Shareholders
Apr 4, 2023 01:12AM Relief Therapeutics Holding SA to Hold Extraordinary General Meeting of Shareholders
Apr 4, 2023 01:12AM Relief Therapeutics Holding SA to Hold Extraordinary General Meeting of Shareholders
Apr 4, 2023 01:12AM Relief Therapeutics Holding SA to Hold Extraordinary General Meeting of Shareholders
Apr 4, 2023 01:12AM Relief Therapeutics Holding SA to Hold Extraordinary General Meeting of Shareholders
Apr 4, 2023 01:12AM Relief Therapeutics Holding SA to Hold Extraordinary General Meeting of Shareholders
Apr 4, 2023 01:12AM Relief Therapeutics Holding SA to Hold Extraordinary General Meeting of Shareholders
Apr 4, 2023 01:12AM Relief Therapeutics Holding SA to Hold Extraordinary General Meeting of Shareholders
Apr 4, 2023 01:12AM Relief Therapeutics Holding SA to Hold Extraordinary General Meeting of Shareholders
Apr 4, 2023 01:12AM Relief Therapeutics Holding SA to Hold Extraordinary General Meeting of Shareholders
Apr 3, 2023 01:30AM Relief Therapeutics Appoints World-Renowned Gene Therapy Pioneer Guangping Gao, Ph.D. as Chair of Scientific Advisory Board
Mar 22, 2023 02:30AM Relief Therapeutics Announces Survey Results Identifying Preferred Urea Cycle Disorder Treatment Attributes Presented by Collaboration Partner at SIMD 2023
Mar 17, 2023 06:25PM Relief Therapeutics to Present Pre-Clinical Evidence for Improved Amino Acid Utilization with PKU GOLIKE at the Society for Inherited Metabolic Disorders 44th Annual Meeting
Mar 16, 2023 02:20AM Relief Therapeutics Announces Availability of New PKU GOLIKE BARs in Europe
Mar 15, 2023 02:30AM Relief Therapeutics Provides Update From Collaboration Partner on OLPRUVA
Feb 28, 2023 01:30AM Relief Therapeutics Recognizes Rare Disease Day and Announces U.S. Availability of New PKU GOLIKE Bars
Feb 14, 2023 01:30AM Relief Therapeutics Announces Enrollment of First Three Patients in Proof-of-Concept Clinical Trial of RLF-TD011 for the Treatment of Epidermolysis Bullosa
Feb 8, 2023 01:30AM Relief Therapeutics Provides an Update on its Financing Strategy
Jan 17, 2023 01:30AM Relief Therapeutics Announces IRB Approval of Investigator-Initiated Trial Evaluating RLF-TD011 as an Adjunctive Treatment for Cutaneous T-Cell Lymphom
View More Recent Stories